Hepatocellular Carcinoma
Conditions
Interventions
Index test:DLR model based on 3D-MRE
Sponsors
Xiangya Hospital Central South University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Inclusion criterias for surgery cohort: 1) patients who underwent mp-MRI and 3D-MRE examinations preoperatively; 2) patients with HCC confirmed by postoperative pathology; 3) an interval of no more than two months between the surgical resection and the MRE examination. 2.Inclusion criterias for immunotherapy cohort: 1) unresectable, locally advanced or metastatic HCC diagnosed histologically or radiologically based on American Association for the Study of Liver Diseases (AASLD) criteria; 2) liver function: Child-Pugh class A; 3) at least one measurable tumor lesion as defined by the modified Response Evaluation Criteria in Solid Tumors (mRECIST); 4) planned treatment with an immune checkpoint inhibitor (ICI)-based regimen as the initial first-line therapy; 5) Eastern Cooperative Oncology Group (ECOG) performance status of 0-1; 6) underwent mp-MRI and 3D-MRE examinations before treatment; 7) Age >= 18 years.
Exclusion criteria
Exclusion criteria: 1.Exclusion criterias for surgery cohort: 1)patients who received any other anti-tumor therapy prior to surgery (e.g., previous surgery, interventional therapy, or systemic therapy); 2) Incomplete 3D-MRE or mp-MRI data, or poor image quality; 3) Incomplete pathological data. 2.Exclusion criterias for immunotherapy cohort: 1) concurrent or history of other active malignancies; 2) prior local therapy for HCC lesions or any systemic therapy other than immunotherapy; 3) lack of regular follow-up imaging examinations; 4) follow-up duration of less than six months; 5) incomplete baseline clinical laboratory data; 6) an interval exceeding half a month between the MRI examination (or clinical laboratory tests) and the initiation of therapy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Positive predictive value;Negative predictive value; | — |
Secondary
| Measure | Time frame |
|---|---|
| sensitivity;specificity; | — |
Countries
China
Contacts
Public ContactLi Mengsi
Xiangya Hospital Central South University
Outcome results
None listed